With Democrats now poised to gain control of both chambers of Congress, AMCP published the following deck to outline the impacts of the 2026 midterm election on federal health policy.
House Energy and Commerce Committee Advances Lower Costs, More Transparency Act
On July 20 and 21, the House Energy and Commerce Committee held a markup of 29 bills pertaining to energy permitting, critical minerals, illicit drugs, and health care price transparency. This includes the Lower Costs, More Transparency Act of 2026 (H.R. 9393), a comprehensive price transparency and health care affordability package led by Chairman Brett Guthrie (R-KY) and Ranking Member Frank Pallone (D-NJ), which advanced for further consideration by the full House of Representatives in a unanimous committee vote.
Related
Cell & Gene Therapies (CGT) offer potentially curative treatment to patients with chronic and hereditary conditions but carry high price tags. One proposal to overcome such financing challenges is to create a national risk pool.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to Medicare Drug Price Negotiation Program: Draft Guidance, Manufacturer Effectuation of the Maximum Fair Price in 2028 (Draft Guidance). CMS issued this draft guidance to describe the processes and requirements for manufacturer effectuation of the maximum fair price (MFP) in 2028 for selected drugs payable under Medicare Part B and/or covered under Medicare Part D.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
